Note: This article is for educational purposes only and should not replace personalized medical advice from your OB-GYN, dermatologist, gastroenterologist, rheumatologist, pharmacist, or your baby’s pediatrician.
Pregnancy has a way of turning even calm, organized adults into late-night search-engine detectives. Add a biologic medication to the mix, and suddenly every thought begins with, “Wait, but what about…?” If you take Tremfya, that feeling is completely understandable.
Tremfya (guselkumab) is a prescription biologic used for plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease. It works by targeting interleukin-23, a protein involved in inflammation. That is helpful when your immune system is acting like it drank three espressos and decided to fight your skin, joints, or digestive tract for sport. But during pregnancy or breastfeeding, the question shifts from “Is this drug working?” to “Is this still the right plan for me and my baby?”
The honest answer is not perfectly tidy. Current guidance does not say Tremfya is proven dangerous in pregnancy. It also does not say it has been fully proven safe. Human pregnancy data are still limited, which means treatment decisions usually come down to a careful, individualized risk-benefit conversation. In other words, this is not the moment for medication roulette.
What the official information says about Tremfya and pregnancy
The prescribing information for Tremfya says that available data in pregnant people are insufficient to establish a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. That wording matters. It does not mean there is a known risk. It means there is not enough human evidence yet to draw a firm conclusion.
There is, however, a pregnancy exposure registry for Tremfya. If a person becomes pregnant while using the medication, they can enroll so researchers can collect more information about outcomes over time. That registry exists because this area is still being studied, and every enrolled pregnancy helps build a clearer picture for future patients.
Animal data add a little nuance and a little caution. In animal studies, no adverse developmental effects were seen at certain exposure levels, but some neonatal deaths were observed in monkeys at higher exposure levels. The label also says the clinical meaning of those findings in humans is unknown. So, no one should pretend the data are perfectly reassuring, but no one should pretend they are a giant red stop sign either.
Why disease control still matters during pregnancy
One of the biggest mistakes in these conversations is focusing only on the medication and forgetting the disease itself. That is a problem because uncontrolled inflammation can also be risky. For example, active inflammatory bowel disease during pregnancy has been linked with worse pregnancy outcomes, including preterm delivery, low birth weight, and babies who are small for gestational age. Severe flares of psoriasis or psoriatic arthritis can also mean more pain, more stress, less sleep, poorer nutrition, and sometimes the need for rescue treatments that are not automatically simpler than staying on the original medication.
So the key question is usually not, “Should everyone stop Tremfya during pregnancy?” The better question is, “What creates the lowest overall risk for this specific patient: staying on therapy, stopping it, or switching to something with more pregnancy data?”
That is why specialists often recommend planning ahead whenever possible. If you are trying to conceive, the smartest move is usually to talk with your care team before pregnancy, not after the positive test and the 2 a.m. panic spiral.
Does Tremfya cross the placenta?
Yes, or at least it is expected to. Tremfya is a monoclonal antibody, and antibodies are transported across the placenta more as pregnancy progresses, especially later in pregnancy. That means fetal exposure is expected to be lower early on and more significant in the second and third trimesters.
This does not automatically mean harm. It does mean timing matters. If Tremfya is used later in pregnancy, your baby’s pediatrician should know about the exposure. That detail can affect how the pediatrician thinks about infection monitoring and vaccine timing, especially with live vaccines. The point is not to sound alarms; it is to make sure everyone in the room is working from the same playbook.
What if you are trying to conceive?
If you are planning pregnancy, it is reasonable to review your medication list early and ask whether Tremfya is still the best choice. At the same time, stopping a biologic without a backup plan can lead to a flare, and flares do not politely wait until your calendar clears.
Current resources say it is not known whether guselkumab makes it harder to get pregnant. That may sound frustratingly vague, but vague is better than fake certainty. At the moment, there is no strong evidence proving Tremfya harms fertility, yet there is not enough research to say the question has been fully settled.
Questions worth asking your clinician include:
- How stable is my disease right now?
- If I stop Tremfya, what are the chances I will flare?
- If I switch medications, what are the tradeoffs?
- Would my pregnancy risk be higher from active disease than from the medication itself?
That conversation may not fit neatly on one sticky note, but it is one of the most important ones you can have before pregnancy.
Tremfya and breastfeeding: what is known so far?
The official medication guide says it is not known whether Tremfya passes into human breast milk. That is the clean, legal, label-approved answer.
But that is not the whole story. MotherToBaby and LactMed add useful context: guselkumab is a very large protein molecule, so only a small amount would be expected to pass into breast milk. And even if a tiny amount does get there, it is likely to be broken down in the infant’s digestive tract, meaning very little would be expected to reach the baby’s bloodstream.
In plain English: the label says “unknown,” but breastfeeding experts do not treat all unknowns equally. Some unknowns are scary black boxes. This one is more of a dimly lit room with a decent floor plan. There are still limited real-world infant data, so caution is appropriate, but the theoretical transfer appears low.
LactMed also notes that some expert guidelines consider guselkumab acceptable during breastfeeding, and that waiting at least two weeks after delivery to resume treatment may further minimize transfer. That does not mean every patient should delay restarting therapy. It means the option may be worth discussing if your disease is stable enough to allow it.
If you breastfeed while taking Tremfya, it is reasonable to watch for signs that your baby is not feeling well, such as fever or frequent infections, and to make sure the pediatrician knows about the medication exposure. Usually, this is less about expecting trouble and more about staying organized and not making your pediatrician guess.
What about fathers or partners taking Tremfya?
Data on paternal exposure are limited, but MotherToBaby notes that, in general, exposures in fathers or sperm donors are unlikely to increase pregnancy risks. That should be reassuring for many couples, even though the research here is not extensive.
Again, this falls into the familiar category of “limited but not especially alarming.” It is not the kind of information that lets you throw confetti, but it is often enough to reduce unnecessary fear.
Vaccines, infections, and other “and more” issues you should not ignore
Tremfya is not just a pregnancy question. It is also an infection and immune-system question. The medication guide warns that Tremfya may increase the risk of infections, and patients should be checked for tuberculosis before starting treatment. Live vaccines should be avoided during treatment, and children should be brought up to date on vaccines before starting Tremfya.
If Tremfya is used during pregnancy, especially later pregnancy, it is smart to tell the baby’s pediatrician. Because monoclonal antibodies can cross the placenta, the pediatrician may want to review the timing of live vaccines rather than simply proceeding on autopilot. That does not mean your child will miss vaccines forever. It means the schedule may need a quick, informed review.
For people taking Tremfya for Crohn’s disease or ulcerative colitis, liver monitoring can also come up during treatment. And for anyone on the drug, new symptoms such as fever, cough, skin sores, unusual fatigue, or signs of an allergic reaction deserve prompt attention. Pregnancy already has enough plot twists; adding an untreated infection is not character development anyone asked for.
Questions to ask your doctor before or during pregnancy
If you take Tremfya and are pregnant, breastfeeding, or planning either, bring these questions to your next visit:
- How much risk comes from my disease being active during pregnancy?
- Do you recommend staying on Tremfya, stopping it, or switching to another treatment?
- If I stay on it, does timing during pregnancy matter?
- Should my baby’s pediatrician know about in-utero exposure before the vaccine schedule is set?
- If I want to breastfeed, what monitoring or precautions make sense?
- Would enrolling in the pregnancy registry be helpful?
A good appointment on this topic should feel like strategy, not guesswork.
The bottom line
Tremfya and pregnancy is one of those topics where simple slogans fall apart fast. The current evidence does not prove Tremfya is harmful in pregnancy, but it also does not provide enough human data to call it fully established as safe. Breastfeeding data are similarly limited, although the biology of the drug suggests milk transfer and infant absorption are likely to be low.
For many patients, the safest decision is not about chasing a perfect answer. It is about balancing limited medication data against the very real risks of uncontrolled psoriasis, psoriatic arthritis, Crohn’s disease, or ulcerative colitis. That balancing act is why a personalized plan matters so much.
If there is one takeaway worth underlining in bold, highlighting in neon, and sticking to the fridge, it is this: do not stop or continue Tremfya based on internet vibes alone. Work with your care team, loop in your pediatrician when needed, and make a decision that protects both disease control and family goals.
Experiences related to Tremfya, pregnancy, breastfeeding, and more
The lived experience around Tremfya and reproductive health is often less dramatic than people fear, but more emotionally complicated than a package insert can capture. Many patients describe the hardest part as the uncertainty. They are not just managing a disease anymore; they are trying to make a responsible decision for a future baby while also protecting their own health. That is a lot to carry, especially when the available evidence is limited rather than absolute.
A common experience starts with someone whose psoriasis, psoriatic arthritis, or IBD is finally stable on Tremfya. Then pregnancy enters the picture, and what felt like a victory suddenly feels fragile. The person may worry that staying on treatment is risky, but they also know what it was like before the medication worked: painful skin, swollen joints, bowel urgency, exhaustion, missed work, and the constant grind of feeling unwell. In real life, this is often the first emotional fork in the road. The fear of medication is competing with the memory of uncontrolled disease.
Another common experience is the “too many opinions” problem. One doctor may focus heavily on the lack of pregnancy data. Another may focus on the dangers of a flare. Online forums can add even more noise, with some people saying, “I stopped immediately,” while others say, “I stayed on my biologic and everything was fine.” That can leave patients feeling like they are expected to make a perfect decision from imperfect information. In practice, what usually helps most is coordinated care: the prescribing specialist, the OB-GYN, and later the pediatrician all speaking the same language instead of handing the patient three different rulebooks.
Breastfeeding adds a second layer of emotion. Many new parents feel pulled between wanting to nurse, wanting to restart effective treatment, and wanting a clear answer that medicine cannot always provide. Some people feel relieved when they learn that large monoclonal antibodies are expected to transfer into milk in very small amounts. Others still decide to pause, switch, or formula feed because peace of mind matters too. That is part of the real experience as well: sometimes the “best” plan is not only about biology, but also about what a parent can realistically live with day to day.
There is also the postpartum piece, which deserves more attention than it gets. After delivery, symptoms can flare, sleep disappears, appointments multiply, and emotional bandwidth shrinks to about the size of a cracker. That is often when medication decisions become urgent again. Some patients want to restart Tremfya quickly because they can feel disease activity creeping back. Others want to wait while they establish breastfeeding. Neither reaction is unusual. What matters is having a plan before that sleep-deprived season arrives, because postpartum decision-making is hard enough without reinventing it at 3:17 a.m.
In short, the real-world experience around Tremfya and pregnancy is usually not one big dramatic moment. It is a series of thoughtful, sometimes stressful decisions about timing, disease control, feeding goals, pediatric follow-up, and personal comfort with uncertainty. And honestly, that is why compassionate, individualized care matters so much.
